Edition:
India

Mylan NV (MYL.OQ)

MYL.OQ on NASDAQ Stock Exchange Global Select Market

39.49USD
2:29am IST
Change (% chg)

$0.82 (+2.12%)
Prev Close
$38.67
Open
$38.57
Day's High
$39.74
Day's Low
$38.36
Volume
1,962,656
Avg. Vol
2,222,143
52-wk High
$45.86
52-wk Low
$29.44

Chart for

About

Mylan N.V. is a global pharmaceutical company. The Company develops, licenses, manufactures, markets and distributes generic, brand name and over-the-counter (OTC) products in a range of dosage forms and therapeutic categories. It operates through three segments on a geographic basis, North America, Europe and Rest of World. The... (more)

Overall

Beta: 1.35
Market Cap(Mil.): $20,534.19
Shares Outstanding(Mil.): 536.28
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 31.14 16.44
EPS (TTM): -- -- --
ROI: -- 14.86 10.62
ROE: -- 16.28 14.20

BRIEF-Mylan Says Teva Has Dismissed Its Pending Litigation Against Co

* MYLAN NV - ANNOUNCED THAT TEVA HAS DISMISSED ITS PENDING DISTRICT COURT LITIGATION AGAINST MYLAN

12:26am IST

BRIEF-Mylan And Aspen Announce Launch Of Generic Busulfex Injection

* MYLAN AND ASPEN ANNOUNCE LAUNCH OF GENERIC BUSULFEX® INJECTION

04 Dec 2017

Sensex snaps four-session losing streak; Infosys gains

Indian shares snapped a four-session losing streak to end higher on Monday, as Infosys Ltd climbed on the appointment of a new CEO and hopes that the software services firm would move past a costly boardroom spat.

04 Dec 2017

Indian shares rise; Infosys jumps as CEO appointment brings peace hopes

Dec 4 Indian stocks rose on Monday as Infosys Ltd rallied on hopes that the appointment of a new CEO would help the company move on from a feud between its board and founders that had pummelled shares.

04 Dec 2017

BUZZ-India's Biocon hits record high on U.S. FDA approval for generic cancer drug Ogivri

** Biocon Ltd jumps as much as 13.8 pct to hit a record high of 509.00 rupees

04 Dec 2017

FDA OKs Mylan's biosimilar of Roche cancer drug Herceptin

The U.S. Food and Drug Administration on Friday approved Mylan NV's biosimilar of Roche's blockbuster treatment for breast cancer, Herceptin, making it the second copycat cancer drug to be approved in the United States.

02 Dec 2017

BRIEF-FDA Approves Mylan's Heparin Sodium Injection

* FDA APPROVAL OF HEPARIN SODIUM INJECTION CONTINUES TO DEMONSTRATE MYLAN'S DEEP EXPERTISE IN DEVELOPING COMPLEX PRODUCTS

01 Dec 2017

FDA approves Mylan's biosimilar of Roche's breast cancer treatment

Dec 1 The U.S. Food and Drug Administration on Friday approved Mylan NV's biosimilar of Roche's blockbuster breast cancer treatment Herceptin.

01 Dec 2017

BUZZ-India's Biocon hits record high; EU regulator OKs marketing applications for generic cancer drugs

** Biocon Ltd jumped as much as 3.6 pct to touch a record high of 447.60 rupees

01 Dec 2017

BRIEF-EMA Accepts Marketing Authorization Applications For Mylan And Biocon's Proposed Biosimilars

* EUROPEAN MEDICINES AGENCY ACCEPTS MARKETING AUTHORIZATION APPLICATIONS FOR MYLAN AND BIOCON'S PROPOSED BIOSIMILARS TRASTUZUMAB AND PEGFILGRASTIM

30 Nov 2017

Earnings vs. Estimates